Join our daily newsletter At The Bell to receive exclusive market insights
- Product presentation and training completed in Dhaka, Bangladesh
- Presented to key decision-makers from the Bangladesh Ministry of Health and Family Welfare
- Discussions focussed on supporting proposed national community screening model
- Proposed program would support Bangladesh’s efforts to achieve the WHO’s cervical cancer screening target of 70% by 2030
TruScreen Group (ASX: TRU) has completed a product presentation and training visit to Dhaka, Bangladesh as part of the company’s expansion across the Indian subcontinent.
.png)
Sumaya Mozumder, BDM for the Indian subcontinent and Dr Carolina Velasquez, medical affairs and training manager, were assisted by TruScreen’s Bangladesh distributor, Xerox Medica, for the visit.
Cervical cancer is the second most common cancer among women in Bangladesh, with an estimated 8,500 new cases and 5,000 deaths each year, the equivalent of around 14 women dying every day.
More than 64 million women aged 15 years and over are at risk, yet estimated screening coverage remains below 10%.
Bangladesh’s national screening program relies on visual inspection with acetic acid (VIA). Discussions reinforced the key barriers to scaling VIA: limited trained personnel to screen every eligible woman; high false-positive rates that require costly recall visits, with many women lost to follow-up; and cultural reluctance among women to undergo invasive pelvic examination.
Executive chairman, Tony Ho, said TruScreen’s non-invasive real-time, AI-enabled device will overcome these barriers. It delivers an immediate result at point of care without laboratory infrastructure or specialist pathology and can be conducted by trained nurses and midwives in community clinics. Women tested with an abnormal result can be referred directly to a specialist.
“Bangladesh has one of the largest under-screened populations in the world, with a government looking for scalable solutions to meet the WHO’s 70% screening target by 2030,” Mr Ho said.
“TruScreen’s portable, non-invasive AI-enabled real-time device allows nurses and midwives to screen women in community clinics with an instant result in the same visit, while giving the Ministry of Health the data it needs to manage a national program.
“With India and Nepal progressing in parallel, the Indian subcontinent is shaping up as a significant growth region for TruScreen.”
In a meeting with a team from the Ministry of Health and Family Welfare at the Directorate General of Health Services (DGHS), discussions centred on deploying TruScreen in community clinics and on TruScreen’s connected screening results portal, which offers the Government access to population-level screening data.
TRU was steady at 0.9¢ with a Mkt cap of $9.061M.
Join the discussion: See what HotCopper users are saying about TruScreen Group and be part of the conversations that move the markets.
The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.
-1200x645-380x200.jpg)
